Latest news and press releases about Novavax, Inc. (NVAX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Novavax, Inc. is a biotechnology firm dedicated to discovering, developing, and commercializing vaccines aimed at preventing serious infectious diseases and addressing critical health needs. The company's diverse pipeline includes NVX-CoV2373, a coronavirus vaccine candidate currently undergoing two Phase III trials, one Phase IIb, and one Phase I/II trial. Also featured is NanoFlu, a nanoparticle-based seasonal quadrivalent influenza vaccine in Phase 3 clinical trials.
Price
| Price | $9.35 |
| Market Cap | $1.5B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -8.07 |
| EV / EBITDA | -8.51 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 159.85% |
| Return on Invested Capital | -36.14% |
| Return on Assets | -25.92% |
| Gross Margin | 77.85% |
| Operating Margin | -54.94% |
| Net Margin | -59.87% |
Related companies: CVAC · NKTR · NTLA · ORIC · PGEN · TERN · TRVI
Explore sector: Healthcare · Biotechnology
More sections of NVAX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks